Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Juin 2024 - 1:00PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that on June 14, 2024, the Compensation Committee of its
Board of Directors granted restricted stock units (RSUs) to 94
employees covering an aggregate of 158,197 shares of common stock
as an inducement material to their entering into employment with
Castle Biosciences. The RSUs were granted pursuant to the Company’s
2022 Inducement Plan in accordance with Nasdaq Listing Rule
5635(c)(4).
The RSUs will vest over four years, with 25% of the shares
vesting on the first anniversary of the applicable vesting
commencement date, and the balance vesting annually thereafter in
three equal installments, subject to the employee’s continued
service through each applicable vesting date.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620340843/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com Media Contact: Allison
Marshall amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Castle Biosciences (NASDAQ:CSTL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
